{"name":"GentiBio, Inc","slug":"gentibio-inc","ticker":"","exchange":"","domain":"gentibio.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPU1dUSkxUeDBLcnNDeFh5RlIyb1VuY1o5Q2VLdDVrTHBObU5udFZyNHpnZjk5REZQNEZzVnU2ZFJSekJ4UW9kYmdzSUs0cnNwaV9Mb3c2cHZJWTFkNGdMbVhjdXllT0JISzVyV1IzTHZaZG1uU1VMS2RZQm5GOWdZQ0k3dWFzdi1SN2p5Wno0OHQ4eTV5X1lZQ2RTaWIwV3dlX2lZNElVTHE4QXlGSlpFY1EwNHZTdw?oc=5","date":"2024-09-30","type":"pipeline","source":"PR Newswire","summary":"GentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical Officer - PR Newswire","headline":"GentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNWU5WNWVCRG1DRjFYWGZRZWFYaXppZFVBZnJtTEVnb1M2RG9WM29OV0laR2Rac2FjRmItYVBwWG5MczFKam84RGNZZXJlbVlEZnNJVThjd1M5NFB3amdBQkMyZGtzbUdJUlYxVmc3UnJobTV1R1d2dnFKNm9mSk1lRTROb1dNY1dPdnRmWW8wLWtYTE9u?oc=5","date":"2024-01-02","type":"pipeline","source":"The Business Journals","summary":"The definitive Boston biotech layoff tracker for 2023 - The Business Journals","headline":"The definitive Boston biotech layoff tracker for 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOZS13dklJbWRlMzVCYWdzS0UyTEJsTzkxTU1aMXVKTjYzQlJOMkFoWmdIQ2haVkZKeEFPMXNKUWdITUlBOGk4QVdMOW5YS09KdFRycjY1ejZMWnZVRXNnWVU1bHlobjFqdWxHNFlhdWZqMHp4WjA3bVktT29JX2Y3blBZRlhkb0Qxc1ItdzZEV1RTQ0NnQjd1d3FQd1p3RDV6YzA1ZW9BSEQzTm1sN2IzMnBYZw?oc=5","date":"2022-09-12","type":"pipeline","source":"citybiz","summary":"Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors - citybiz","headline":"Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQOVJmV2J5ZHpMaXNjRm1aSTdsVC02YktTazNNOVpQRnp1MkFYZERSVWxCLVVnWE5Vb0dtTE1tWjgyWGlpYlR4NHIxeG9qN1F1NVpvdWlrTDZyaWVYSGZlRGdJSGxZYVBMMDFXbUFqclcxNW15a2pDTlZtYXdNME15dVdNeXpHMVhndnRwMHdyQQ?oc=5","date":"2022-08-16","type":"deal","source":"Seattle Children's","summary":"Partnering with Biotechs to Save Lives - Seattle Children's","headline":"Partnering with Biotechs to Save Lives - Seattle Children's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQWUJLdWRxVjZPQkUzd3hXcThlSXlSOTFvRndWY1d4VXlXcG9UMmFTVVg0SlM4aUlwQVFWMEh5eVV4c0VSM0x4dVFfRUxEQW1Bem1JaThqT0RuVVR4d0lLS3VJeURtelZsaDBXMkI5V3VmRXVZRThISk1PRmNnYUNNa2FXNlZWeFBkLVV2NGRKQ1dtUGE4YVVDVlp0MmJpNDJYV0pqVnVCMElkdTFOc3EtYkVVSnowbnhDZFN1d2dnX2wxdw?oc=5","date":"2022-08-10","type":"regulatory","source":"Fierce Biotech","summary":"BMS bites at GentiBio's next-gen regulatory T cells, betting $1.9B on 3 programs - Fierce Biotech","headline":"BMS bites at GentiBio's next-gen regulatory T cells, betting $1.9B on 3 programs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOXzFFdGR1WmwtekphRGNBN1EyWmpDVVd6V0VBV0JEQVVmZXlLTVF4NkZNdzJwQUFScjdSSDFBY0UxYVprSkZNMHBPUkY5X3JGeGc0ZnJZZHlYZXNyYTQzSFdmd3ZPOWs2TUJJYzFMN2lHQnlEMVY2Nml1M0Q1Rl8tQTY5akVBZWQ5ZmNFWTJVZTQ?oc=5","date":"2022-08-10","type":"deal","source":"BioPharma Dive","summary":"GentiBio partners with Bristol Myers as cell therapy for immune disease gains momentum - BioPharma Dive","headline":"GentiBio partners with Bristol Myers as cell therapy for immune disease gains momentum","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQOFJlQXZoTE5xVmxMUnFrMU13SjBudGJGMFZmREN6WGxBbWRDNHc1ZGxzS0swaUxaeXkzcHBHUTNLTnpfU0NKV2dCOWxFZ09ucjM2Rk9ZVGcxRUNVaXZHWUVDQVp0MnZTbHdyN1VPX0NJUzdlVlhhT1FjN2xMOTZIV0VKZzV1Zw?oc=5","date":"2022-08-10","type":"deal","source":"pharmaphorum","summary":"BMS adds to IBD pipeline with $1.9bn GentiBio deal - pharmaphorum","headline":"BMS adds to IBD pipeline with $1.9bn GentiBio deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPTjM2R2hlcXpkbU14MklNT2N0NnF0emQ4Y0RubGpsdmtHSzI3NU9yZXZzMzZGT0FsSEwzMUFRMk1fY2NSajlEcU5PbXBoRzN2RGZnQ1hRaUJlRmo4eXlqbi0xQVpvVlk3Ujl5Z29kRkZONHptc1V4aU1KR1E2b2dIRlplY2Fpak5nMC1qSEREOV9UOEZNaVltYV92QQ?oc=5","date":"2022-08-10","type":"pipeline","source":"BioSpace","summary":"BMS Bets up to $1.9 Billion on GentiBio’s Treg Platform for IBD - BioSpace","headline":"BMS Bets up to $1.9 Billion on GentiBio’s Treg Platform for IBD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9yRE95OFVmS3dqUnlBS09HSWtlZVlGSmJuVDdaRV9Lak1oMHU0TjE0M1VHdEZfZ0RtQzBYbTVtSHRGQ1VxUXkzYTFqQ3lVaUFhYlI3c2dmQmRua0FqRjJHQzhCRHFXalB2aW9lRkdHcUlCZ204TTdLd0tB?oc=5","date":"2022-01-02","type":"pipeline","source":"BioSpace","summary":"Biggest Biopharma Successes and Flops of 2021 - BioSpace","headline":"Biggest Biopharma Successes and Flops of 2021","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPZnhpM21Ga2VzcGxMYzJVUkVoT3RCZWJ3bUx1QjRJRG5zQmQ3SC12TTlxRTFPUlRKd0ZTUUxadzFTWHFQeTU5TUtKcU9USFh3Qm1CNWU0ZG8yZ09fVzZOTmY4czBDLURtNFBiTFJOOEZpeVp1Q1RCYm1GVGFqQW9jR2dFT0lrRmJxQXE2QXh3czBsbTRscE44Vy1mZDhYX0lxdUdYWjZWUXp6MS1SeHZXRV9lbk8?oc=5","date":"2021-07-16","type":"pipeline","source":"Contract Pharma","summary":"GentiBio, Forge Biologics Ink Development and Manufacturing Agreement - Contract Pharma","headline":"GentiBio, Forge Biologics Ink Development and Manufacturing Agreement","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}